These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 17407631)
1. Dihydroergotamine nasal spray for relief of refractory headache: a retrospective chart review. Fisher M; Gosy EJ; Heary B; Shaw D Curr Med Res Opin; 2007 Apr; 23(4):751-5. PubMed ID: 17407631 [TBL] [Abstract][Full Text] [Related]
2. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study. Weintraub J Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862 [TBL] [Abstract][Full Text] [Related]
3. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children. Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454 [TBL] [Abstract][Full Text] [Related]
4. Dihydroergotamine nasal spray in the treatment of acute migraine. Treves TA; Kuritzky A; Hering R; Korczyn AD Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305 [TBL] [Abstract][Full Text] [Related]
5. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452 [TBL] [Abstract][Full Text] [Related]
7. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293 [TBL] [Abstract][Full Text] [Related]
8. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611 [TBL] [Abstract][Full Text] [Related]
9. Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review. Srouji R; Schenkel SR; Forbes P; Cahill JE Headache; 2021 May; 61(5):777-789. PubMed ID: 34105158 [TBL] [Abstract][Full Text] [Related]
10. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. Albrecht D; Iwashima M; Dillon D; Harris S; Levy J Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049 [TBL] [Abstract][Full Text] [Related]
12. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953 [TBL] [Abstract][Full Text] [Related]
13. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Ford RG; Ford KT Headache; 1997 Mar; 37(3):129-36. PubMed ID: 9100396 [TBL] [Abstract][Full Text] [Related]
14. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235 [TBL] [Abstract][Full Text] [Related]
15. Exacerbation of SUNCT and SUNA syndromes during intravenous dihydroergotamine treatment: A case series. Lambru G; Shanahan P; Matharu M Cephalalgia; 2015 Oct; 35(12):1115-24. PubMed ID: 25667300 [TBL] [Abstract][Full Text] [Related]
16. Dihydroergotamine nasal spray for the acute treatment of migraine. Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914 [TBL] [Abstract][Full Text] [Related]
17. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Andersson PG; Jespersen LT Cephalalgia; 1986 Mar; 6(1):51-4. PubMed ID: 3516408 [TBL] [Abstract][Full Text] [Related]
18. Aprepitant for the management of nausea with inpatient IV dihydroergotamine. Chou DE; Tso AR; Goadsby PJ Neurology; 2016 Oct; 87(15):1613-1616. PubMed ID: 27629088 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Aurora SK; Rozen TD; Kori SH; Shrewsbury SB Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249 [TBL] [Abstract][Full Text] [Related]
20. Enhancing Outpatient Dihydroergotamine Infusion With Interdisciplinary Care to Treat Refractory Pediatric Migraine: Preliminary Outcomes From the Comprehensive Aggressive Migraine Protocol ("CAMP"). Connelly M; Sekhon S; Stephens D; Boorigie M; Bickel J Headache; 2020 Jan; 60(1):101-109. PubMed ID: 31626335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]